Latest FDA Stories
FDA’s new proposed rules will make drug manufacturers revamp the way they register data on ClinicalTrials.gov.
- In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure NORTH CHICAGO, Ill., Dec.
Implants constructed from a novel porous resorbable biomaterial offer surgeons an attractive alternative to allograft WOBURN, Mass., Dec.
Increasingly FDA warning letters to GMP facilities cite violations in raw materials management.
ThermiAesthetics' Patients Show Significant Results with New, FDA-Cleared Device Southlake, TX (PRWEB) December 17, 2014 Radiofrequency is a staple
Biosimilar stakeholders urge the FDA to pass final regulations related to the drugs at a recent conference on biosimilars, reports Atlantic Information Services’ Specialty Pharmacy News in its
Power morcellators first came to market decades ago, under the FDA’s 510(k) clearance program, which in most cases does not require controlled human testing. New
Breakthrough Surgical Sealant Designed to Help Reduce Anastomotic Leaks for Patients Undergoing Gastrointestinal Resections PITTSBURGH, Dec.
Fourth Quarter Milestone Achievements Increase Customer Base, Spur Sales and Marketing Expansion SARATOGA, Calif., Dec.
CYRAMZA is the first treatment approved in the U.S. for use in combination with docetaxel in second-line metastatic non-small cell lung cancer INDIANAPOLIS, Dec.